UK markets closed

AgeX Therapeutics, Inc. (AGE)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
0.7800+0.0800 (+11.43%)
At close: 03:50PM EDT
0.8000 +0.02 (+2.56%)
After hours: 05:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.7000
Open0.7350
Bid0.7104 x 2900
Ask0.8130 x 1800
Day's range0.7104 - 0.8157
52-week range0.5160 - 1.7700
Volume65,890
Avg. volume53,738
Market cap29.596M
Beta (5Y monthly)1.39
PE ratio (TTM)N/A
EPS (TTM)-0.2450
Earnings date10 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors

    ALAMEDA, Calif., May 18, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Dr. Joanne Hackett has been appointed Chairperson of AgeX’s Board of Directors. Dr. Hackett joined the Board of Directors in December 2021. She will serve in a non-executive capacity as AgeX’s Chairperson. Dr. Greg Bailey, who served as AgeX’s Chairperson since 2018, will continue to serve as a member of AgeX’s

  • Business Wire

    AgeX Therapeutics Reports First Quarter 2022 Financial Results

    ALAMEDA, Calif., May 13, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2022.

  • Business Wire

    AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results

    ALAMEDA, Calif., March 29, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2021.